Phathom Pharmaceuticals
Logotype for Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals (PHAT) investor relations material

Phathom Pharmaceuticals Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Phathom Pharmaceuticals Inc
Jefferies Global Healthcare Conference summary18 Nov, 2026

Commercial progress

  • VOQUEZNA launched at the end of 2023; sales were $55 million in its first full commercialization year and $175 million last year, with FY2026 guidance of $310 million-$325 million.

  • Indicated for erosive esophagitis and non-erosive reflux, VOQUEZNA provides elevated stomach pH over 24 hours and targets patients who remain symptomatic on PPIs.

  • In market research, 97% of surveyed gastroenterologists viewed VOQUEZNA as a better treatment for heartburn patients.

Prescribing access and GI growth

  • Commercial coverage exceeds 80% of lives and has been generally stable; the key prescribing friction is prior authorization workflow and physician confidence in fulfillment, rather than a change in coverage.

  • BlinkRx supports PA submission, resubmissions and appeals, and offers cash pay when insurance does not cover the drug; commercial patients using BlinkRx can access a $0 copay versus $25 through retail.

  • The GI path to $1 billion in sales targets 20%-30% of 20 million annual acid-suppression prescriptions; VOQUEZNA currently represents 5%-6% of those scripts.

  • Broader use depends on moving from the most severe patients to moderately severe patients as physicians gain confidence in treatment and fulfillment.

Primary care and promotion

  • A further $1 billion sales opportunity is envisioned in primary care; current sales calls are 70% GI and 30% primary care, with plans to broaden primary-care capabilities over time.

  • Digital DTC outreach restarted in 2026 after much promotion was paused in H2 2025; channel pilots are starting modestly, with investment to grow where ROI is positive.

  • A newly started as-needed dosing study is part of the primary-care expansion strategy, addressing patients seeking an alternative to daily PPI therapy.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Phathom Pharmaceuticals earnings date

Logotype for Phathom Pharmaceuticals Inc
Q4 202625 Feb, 2027
Phathom Pharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Phathom Pharmaceuticals earnings date

Logotype for Phathom Pharmaceuticals Inc
Q4 202625 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Phathom Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s research is centered around novel therapies that address acid-related disorders, such as gastroesophageal reflux disease (GERD) and related conditions. Phathom aims to provide new treatment options that improve the management of these chronic conditions, particularly in areas where current therapies may be inadequate. The company is headquartered in Florham Park, New Jersey, and its shares are listed on the NASDAQ.